Vensana Capital I GP, LLC - 05 Feb 2026 Form 3 Insider Report for SpyGlass Pharma, Inc. (SGP)

Role
10%+ Owner
Signature
/s/ Steven Schwen, Chief Financial Officer of Vensana Capital I GP, LLC
Issuer symbol
SGP
Transactions as of
05 Feb 2026
Net transactions value
$0
Form type
3
Filing time
05 Feb 2026, 16:24:19 UTC
Next filing
10 Feb 2026

Reporting Owners (4)

Name Relationship Address Signature Signature date CIK
Vensana Capital I GP, LLC 10%+ Owner 3601 W. 76TH STREET, SUITE 20, EDINA /s/ Steven Schwen, Chief Financial Officer of Vensana Capital I GP, LLC 05 Feb 2026 0001854073
Vensana Capital I, L.P. 10%+ Owner 3601 W. 76TH STREET, SUITE 20, EDINA /s/ Steven Schwen, Chief Financial Officer of Vensana Capital I GP, LLC, the general partner of Vensana Capital I, L.P. 05 Feb 2026 0001757539
Nielsen Kirk G. 10%+ Owner 3601 W. 76TH STREET, SUITE 20, EDINA /s/ Steven Schwen, as attorney-in-fact for Kirk Nielsen 05 Feb 2026 0001523522
Klein Peter Justin 10%+ Owner 3601 W. 76TH STREET, SUITE 20, EDINA /s/ Steven Schwen, as attorney-in-fact for Peter Justin Klein 05 Feb 2026 0001608710

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SGP Series B Preferred Stock 05 Feb 2026 Common Stock 1,690,230 See Footnote F1, F2
holding SGP Series C-1 Preferred Stock 05 Feb 2026 Common Stock 548,067 See Footnote F1, F2
holding SGP Series C-2 Preferred Stock 05 Feb 2026 Common Stock 548,067 See Footnote F1, F2
holding SGP Series D Preferred Stock 05 Feb 2026 Common Stock 359,255 See Footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All shares of the preferred stock, par value $0.00001 per share, of the Issuer will automatically be converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
F2 These shares are held directly by Vensana Capital I, L.P. ("Vensana I"). Vensana Capital I GP, LLC ("Vensana GP I") is the general partner of Vensana I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein (the "GP I Managing Directors") are the managing directors of Vensana GP I. Each of Vensana GP I and the GP I Managing Directors, in their capacities with respect to Vensana GP I, may be deemed to have voting, investment and dispositive power with respect to the shares held by Vensana I. Each of Vensana GP I and the GP I Managing Directors disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of Vensana GP I or the GP I Managing Directors is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.

Remarks:

Exhibit 24 - Power of Attorney